Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Down 6.3% in December

Dynavax Technologies Co. (NASDAQ:DVAX) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 16,780,000 shares, a drop of 6.3% from the November 30th total of 17,900,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the short-interest ratio is presently 8.0 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 1,172 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 1,484 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

Dynavax Technologies stock traded down $0.06 during mid-day trading on Wednesday, hitting $12.77. 948,101 shares of the company traded hands, compared to its average volume of 2,094,966. The stock has a fifty day moving average price of $12.52 and a 200-day moving average price of $11.55. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 98.24 and a beta of 1.33. Dynavax Technologies has a one year low of $9.74 and a one year high of $15.01. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.